Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. R. [1 ]
Wiessalla, S. [1 ]
Shahinfar, M. [1 ]
Shafaei, S. [1 ]
Kropf, S. [2 ]
Wester, H. J. [3 ,4 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, THERANOST Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Scintomics GmbH, Fuerstenfeldbruck, Germany
[3] Tech Univ Munich, Fac Chem, D-80290 Munich, Germany
[4] Tech Univ Munich, Fac Med, D-80290 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP291
引用
收藏
页码：S224 / S225
页数：2
相关论文
共 50 条
  • [21] COMPARISON OF GA-68 DOTATATE SCANNING AND LU-177 DOTATATE SCANNING IN NET PATIENTS UNDERGOING PRRT
    Bency, R.
    McKay, E.
    Farlow, D.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 22 - 22
  • [22] Outcome of Peptide Receptor Radionuclide Treatment with Lu-177 DOTATATE from Ankara University.
    Soydal, C.
    Peker, A.
    Ozkan, E.
    Kucuk, O. N.
    Kir, M. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [23] Effectivity and Toxicity of Salvage PRRT with Lu-177 DOTATATE in patients with progressive, metastasized NET
    Rudisile, Simon
    Gosewisch, Astrid
    Gildehaus, Franz Josef
    Boening, Guido
    Auernhammer, Christoph
    Bartenstein, Peter
    Todica, Andrei
    Ilhan, Harun
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [24] Methodological Effects in Kidney Dosimetry in Lu-177 Radionuclide Therapy
    Heikkonen, J.
    Maenpaa, H.
    Tenhunen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S265 - S265
  • [25] Radiation Dosimetry Aspects of Lu-177
    Lassmann, Michael
    Eberlein, Uta
    CURRENT RADIOPHARMACEUTICALS, 2015, 8 (02) : 139 - 144
  • [26] Evaluation of thyroid function in patients receiving Lu-177 DOTATATE treatment
    Kibar, A.
    Ince, B.
    Nazari, A.
    Toplutas, K. N.
    Bilgic, S.
    Asa, S.
    Besli, R. L. Uslu
    Sager, M. S.
    Sayman, H. B.
    Sonmezoglu, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S470 - S470
  • [27] Lu-177 Lutetium Dotatate Infusion Safety: Infiltration or Extravasation?
    Valencia, Brooke
    Peterson, Heather
    Huber, Casey
    Gansen, Denise
    Kendi, Ayse
    Paulsen, Andrew
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [28] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    Targeted Oncology, 2024, 19 : 41 - 49
  • [29] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
  • [30] Short-term Haematological and Biochemical Safety of Lu-177 DOTATATE Therapy
    Kauppila, E.
    Allen, R.
    Ifigeneia, K.
    Meades, R.
    Tan, T.
    Barwick, T.
    Soneji, N.
    Al-Nahhas, A.
    Win, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S587 - S587
12345